flex fertilizer foliar n-18 flydende middel
flex fertilizer system aps - magnesium, kvælstof, calcium - flydende middel - 9 g/l magnesium ; 177 g/l kvælstof (næringsstof) ; 47 g/l calcium
buvidal
camurus ab - buprenorphin - opioid-relaterede lidelser - andre narkotika stoffer - behandling af opioidafhængighed inden for rammerne af en medicinsk, social og psykologisk behandling. behandlingen er beregnet til brug hos voksne og unge i alderen 16 år eller over.
remix flydende middel
adama northern europe b.v. - uspecificeret - flydende middel - 0 g/l uspecificeret
seamac 45 flydende middel
fmc europe nv, agrochemical products group - ascophyllum - flydende middel - 450 g/l ascophyllum nodosum
heplisav b
dynavax gmbh - hepatitis b overflade antigen - hepatitis b - vacciner - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations. it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiske midler - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
sprycel
bristol-myers squibb pharma eeig - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiske midler - sprycel er indiceret til behandling af pædiatriske patienter med nyligt diagnosticeret philadelphia-kromosom-positiv kronisk myeloid leukæmi i kronisk fase (ph+ cml cp) eller ph+ cml cp resistente eller intolerant over for tidligere behandling, herunder imatinib. nydiagnosticerede ph+ akut lymfoblastær leukæmi (all) i kombination med kemoterapi. sprycel er indiceret til behandling af voksne patienter med nyligt diagnosticeret philadelphia-kromosom-positiv (ph+) kronisk myeloid leukæmi (cml) i den kroniske fase;kronisk, accelereret eller blast-cml-fase med resistens eller intolerans til forudgående behandling, herunder imatinib mesilate;ph+ akut lymfoblastær leukæmi (all) og lymfoid blast-cml med modstand eller intolerance over for tidligere behandling. sprycel er indiceret til behandling af pædiatriske patienter med nyligt diagnosticeret ph+ cml i kronisk fase (ph+ cml-cp) eller ph+ cml-cp resistente eller intolerant over for tidligere behandling, herunder imatinib.
corpin 25 mikrogram+2 mg injektionsvæske, opløsning
evolan pharma ab - aviptadil, phentolaminmesilat - injektionsvæske, opløsning - 25 mikrogram+2 mg
invicorp 25 mikrogram+2 mg injektionsvæske, opløsning
evolan pharma ab - aviptadil, phentolaminmesilat - injektionsvæske, opløsning - 25 mikrogram+2 mg
procivni 25 mikrogram+1 mg injektionsvæske, opløsning
evolan pharma ab - aviptadil, phentolaminmesilat - injektionsvæske, opløsning - 25 mikrogram+1 mg